Pre-Black-Friday Vendor Drop Syndrome

Patient abandons a perfectly functional caloric deficit the moment a sketchy Telegram channel posts a countdown timer.

Filed under Retatrutide ·Survodutide ·Mazdutide · #glp-1 ·#stack-life ·#cope

Active Compounds

Retatrutide · Triple GIP/GLP-1/Glucagon Receptor Agonist

An investigational triple agonist (GIP/GLP-1/glucagon) from Eli Lilly. Not FDA-approved. Phase III TRIUMPH-4 results showed 23.7% weight loss — the most of any obesity drug in development.

Survodutide · Dual Glucagon/GLP-1 Receptor Agonist

An investigational dual glucagon/GLP-1 receptor agonist from Boehringer Ingelheim and Zealand Pharma. Phase 3 SYNCHRONIZE-1 (April 28, 2026 topline) achieved 16.6% mean weight loss at 76 weeks — the first positive Phase 3 readout in the SYNCHRONIZE obesity program. FDA Fast Track (2021) and Breakthrough Therapy (2024) designations for MASH; full SYNCHRONIZE-1 data at ADA June 2026.

Mazdutide · Incretin Mimetic

The world's first approved dual GLP-1/glucagon receptor agonist, developed by Innovent Biologics (China). Approved in China for obesity and type 2 diabetes. Phase 3 trials showed up to 20.1% weight loss.

RX: Retatrutide · Survodutide · Mazdutide
Dosage: 1 vendor drop
Half-life: until checkout closes
Source: manual
Tags: glp-1 , stack-life , cope
Stamped: 2026-05-31 · Cycle 022
Lot #: LOT-20260531T18:33:49.380Z